Your browser doesn't support javascript.
Impact of a Pharmacist-Managed Procalcitonin Program on COVID-19 Respiratory Tract Infection Outcomes and Health Care Resource Utilization.
Fratoni, Andrew J; Kois, Abigail K; Colmerauer, Jessica L; Linder, Kristin E; Nicolau, David P; Kuti, Joseph L.
  • Fratoni AJ; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
  • Kois AK; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
  • Colmerauer JL; Department of Pharmacy Services, Hartford Hospital, Hartford, Connecticut, USA.
  • Linder KE; Department of Pharmacy Services, Hartford Hospital, Hartford, Connecticut, USA.
  • Nicolau DP; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
  • Kuti JL; Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Open Forum Infect Dis ; 9(9): ofac468, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-2051514
ABSTRACT
Patients hospitalized with coronavirus disease 2019 (COVID-19) often receive empiric antibiotic coverage. Procalcitonin (PCT) is a biomarker with Food and Drug Administration-approved guidance cutoffs for antibiotic use in lower respiratory tract infections. Herein we describe the implementation and impact of a pharmacist-managed PCT monitoring program in hospitalized patients with COVID-19. In this quasi-experimental, single-center, retrospective study of a prospective antimicrobial stewardship pharmacist-managed program, inpatients who were severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction positive were reviewed during weekday working hours and evaluated for appropriateness of antibiotic treatment by utilizing the PCT biomarker. As needed, the infectious diseases pharmacist offered feedback around antibiotic discontinuation in patients with PCT values ≤0.25 ng/mL. Adherence to PCT cutoffs, clinical outcomes, and utilization of health care resources were quantified and compared with a time frame immediately preceding the program's implementation. A total of 772 patients hospitalized with COVID-19 were analyzed. The pre-intervention cohort was comprised of 519 patients, and 253 patients were included after program implementation. Antibiotics were prescribed within 72 hours of admission to 232 (44.7%) and 108 (42.7%) patients during the control and intervention phases, respectively. There was no difference in the primary outcome of percentage of patients who received >1 day of antibiotic therapy (23.5% vs 21.7%; P = .849) or in any secondary outcome including hospital length of stay, 30-day readmission rates, or discharge disposition. In a hospital where the majority of COVID-19 patients did not receive empiric antibiotics, the implementation of a pharmacist-managed PCT monitoring program did not significantly decrease antibiotic use or health care resource utilization.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Language: English Journal: Open Forum Infect Dis Year: 2022 Document Type: Article Affiliation country: Ofid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Language: English Journal: Open Forum Infect Dis Year: 2022 Document Type: Article Affiliation country: Ofid